Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Melanoma (Skin Cancer) Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Melanoma (Skin Cancer). Eligibility criteria explained in plain English.

TrialFinderData lists 4 Melanoma (Skin Cancer) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 is the largest group at 50% (1 studies); the largest phase groups are Phase 1: 1, Early Phase 1: 1.

Research is led by Xijing Hospital (2), Hefei TG ImmunoPharma Co., Ltd. (1), Elephas (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is TGI-5 (drug, 1 trial), followed by Cadonilimab and Recombinant Human Interferon α1b Combination Therapy, Low Branched-Chain Amino Acid Diet.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
0
Phase 3 Trials
3
Sponsors

Track Melanoma (Skin Cancer) trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT07376707

A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic...

This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary antitumor activity of TGI-5 as monotherapy and in...

Sponsor: Hefei TG ImmunoPharma Co., Ltd.Enrolling: 1941 location
RECRUITINGEarly Phase 1NCT07586904

Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.

1. Primary Objective To evaluate the efficacy and safety of cadonilimab in combination with high-dose recombinant human interferon α1b injection as neoadjuvant therapy in...

Sponsor: Xijing HospitalEnrolling: 101 location
RECRUITINGNCT07586891

Exploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet...

1. Primary Objective: To evaluate the safety of a low branched-chain amino acid diet (60% of the normal dietary BCAA content) combined with anti-PD-1 monoclonal antibody as...

Sponsor: Xijing HospitalEnrolling: 801 location
RECRUITINGNCT07327489

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a...

Sponsor: ElephasEnrolling: 20008 locations

Frequently Asked Questions

There are currently 4 clinical trials for Melanoma (Skin Cancer), with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Melanoma (Skin Cancer), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Melanoma (Skin Cancer), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.